BLOOMFIELD, Conn., April 9, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) has been recognized for excellence in employee health and well-being by the Business Group on Health, and for its commitment to health equity. This marks the 17th consecutive year the company has been recognized for its commitment to advancing employee well-being through comprehensive and innovative benefits and initiatives.
"We believe that employers play a vital role in the health care system, and we strive to be a model for others by prioritizing the health and vitality of employees within our own company," said Kari Knight Stevens, chief human resource officer, The Cigna Group. "A healthy and diverse workforce is essential to achieving our mission, and we continually invest in our employees to support their health and vitality."
The Cigna Group's health and well-being initiatives address and support the eight dimensions of vitality—financial, physical, emotional, social, intellectual, environmental, spiritual, and occupational—to give our employees the tools to prioritize all areas of their well-being. Examples of this work include:
The Business Group on Health assesses organizations based on their approach to leadership, strategy, and culture; holistic well-being, including mental health, financial security, physical health, social connectedness, and job satisfaction; engagement and the employee experience; health equity; and metrics and evaluation.
About The Cigna Group
The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has more than 165 million customer relationships around the world. Learn more at thecignagroup.com.
Media Contact
Madeline Ziomek
(202) 615-1473
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$341.70 |
Daily Change: | 1.14 0.33 |
Daily Volume: | 536,772 |
Market Cap: | US$95.520B |
September 12, 2024 September 12, 2024 August 01, 2024 May 23, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB